(S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester

Product Name (S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester
Alias (S)-Boc-pyroglutamic acid
Einecs 'EINECS 251-300-6'
Mininmum Order 1g
Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
Price Inquiry sales9@bouling-chem.com
Manufacturer Bouling Chemical Co., Limited
CONTACT NOW

In terms of specification, (S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester is supplied with ≥98% HPLC purity and specific rotation [α]D²⁰ = –60° to –62° (c=1, MeOH), making it suitable for solid-phase peptide synthesis.

Specifications

HS Code	681349
Chemical Name	(S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester
Molecular Formula	C11H19NO4
Molecular Weight	229.27
Appearance	Typically a solid (description may vary based on purity and conditions)
Melting Point	Can vary depending on purity, might be a specific value within a certain range
Solubility	Solubility in organic solvents like dichloromethane, less soluble in water
Density	Estimated density based on related compounds and structure
Chirality	Has (S)-configuration, is chiral
Flash Point	Unknown, but can be estimated based on similar esters
Pka	Related to the acidic nature of the carboxylic acid moiety (approximate value based on similar structures)

As an accredited (S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

Packing & Storage

Packing	500g of (S)-1,2 - Pyrrolidinedicarboxylic Acid 1-(1,1 - Dimethylethyl) Ester in sealed, labeled containers.
Shipping	( S ) -1,2 -Pyrrolidinedicarboxylic Acid 1-(1,1 -Dimethylethyl) Ester is shipped in accordance with chemical transport regulations. It's carefully packaged to prevent breakage and leakage, ensuring safe transit to the destination.
Storage	( S ) -1,2 - Pyrrolidinedicarboxylic Acid 1 - (1,1 - Dimethylethyl) Ester should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could potentially lead to degradation. Store in a well - ventilated area, isolated from incompatible substances to avoid chemical reactions.

Application of (S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester

Loading of Boc-Pro-OH onto chloromethylated cross-linked polystyrene resin requires strict stoichiometric control of the cesium carbonate neutralization step because excess base promotes diketopiperazine formation on Pro-containing dipeptidyl-resin constructs. A validated protocol on a 50 L solid‑phase synthesis column (Büchi Sepacore, glass‑lined, bottom‑filter membrane 20 µm PTFE) charges resin pre‑swollen in DMF (swelling factor 4.2 mL/g) with a solution of Boc-Pro-OH (3.0 eq relative to amine loading), DIC (3.0 eq), and HOBt monohydrate (3.0 eq) at 0–5 °C; the mixture is circulated with nitrogen bubbling for 4 h, achieving coupling efficiency >99.2% by Kaiser test and Fmoc‑release UV monitoring at 301 nm. To preclude epimerisation at the proline α‑carbon, the activation temperature is maintained below 8 °C and the batch is sampled every 30 min for chiral HPLC (Chirobiotic T column, 250 × 4.6 mm, mobile phase MeOH/water 60:40 with 0.1% TFA, flow 0.8 mL/min, D‑Pro‑containing diastereomer eluting at 11.2 min, acceptance limit <0.5% AAC). The resin is then capped with Ac₂O/pyridine (1:1, 2 × 15 min) and sequential BOC‑deprotection ( 50% TFA in DCM, 2 × 30 min) followed by neutralisation (5% DIEA in DMF) proceeds with intermittent DMF washes monitored by conductivity (<50 µS/cm endpoint). After chain elongation, the peptidyl‑resin is cleaved using anhydrous HF containing 10% anisole and 5% dimethyl sulfide at −5 °C for 60 min (Peptide International HF apparatus, Kel‑F vessel); scavenger removal and ether precipitation and lyophilisation afford the linear crude peptide carrying the Pro residue. Commercial calibrants include a therapeutic pentapeptide analogue (thymopentin backbone) where the Pro‑⁶ position is quantitatively introduced via this Boc‑Pro‑OH strategy, and the API is released against Ph. Eur. 2.2.56 amino acid analysis with a Pro recovery of 98.0–102.0%. Process‑scale GMP production operates under ICH Q7 and 21 CFR 211, and resin‑bound intermediate sampling follows a pre‑established process analytical technology (PAT) framework with in‑line Raman probe measuring the C=O ester stretch at 1738 cm⁻¹.

Comparative activation method performance during Boc-Pro-OH‑mediated dipeptide formation on trityl‑chloride resin (**1.0 mmol/g**)
Activation method	Coupling time (h)	Yield (%)	D‑Pro isomer (%)	Observed side reaction
DIC/HOBt (3 eq) in DMF, 5°C	4.0	99.2	<0.3	Oxazolone condensation trace
HATU/DIEA (3 eq) in DMF, 25°C	1.5	98.5	1.8	Lactam formation on Pro
EDC/HOAt (3 eq), NMM, 10°C	6.0	96.0	0.4	N‑Acylurea adduct
Mixed anhydride (IBCF/NMM) in THF, −15°C	2.0	97.8	<0.1	Urethane by‑product

Reduction of Boc-Pro-OH to (S)-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert‑butyl ester (Boc‑prolinol) with NaBH₄–I₂ in anhydrous THF at 0–5 °C generates a chiral alcohol that serves as the key intermediate for oxazaborolidine catalysts used in industrial asymmetric ketone reduction. A 20 L jacketed glass reactor (Schott Duran, argon‑flushed, internal probe thermometer) is charged with Boc-Pro-OH (1.0 mol, 215.2 g) and powdered NaBH₄ (2.5 mol, 94.6 g) suspended in THF (8.0 L, freshly distilled from Na/benzophenone); a solution of iodine (1.25 mol, 317.5 g) in THF (2.0 L) is added via syringe pump at a rate of 6.0 mL/min to keep the internal temperature below 8 °C. After gas evolution ceases, the mixture is refluxed for 3 h, quenched with methanol, filtered through Celite, and concentrated. The resulting oil is purified by short‑path distillation (boiling range 112–115 °C at 0.3 mbar), affording Boc‑prolinol with optical rotation [α]²⁵_D −42° (c=1, CHCl₃; measured on Autopol VI, 589 nm). Residual iodine is controlled below 10 ppm by ion chromatography (USP <621>). Operating under an inert atmosphere with moisture content verified below 30 ppm (Karl Fischer coulometer, ASTM E203‑16) prevents deactivation of the subsequent borane‑complex step. The resulting Boc‑prolinol is treated with methanolic HCl to remove the Boc group, and the free amine reacts with trimethylboroxine to yield (S)-2‑methyl‑CBS‑oxazaborolidine (Corey–Bakshi–Shibata catalyst) that is used at 10 mol% loading for the enantioselective reduction of prochiral ketones; one documented finished application is the key step in the synthesis of (S)-duloxetine intermediate, where 95% ee is consistently achieved under optimised conditions with BH₃·SMe₂ in toluene at −20 °C. Full‑scale production embraces a quality‑by‑design protocol with a design space for the reduction temperature bracketing 0–10 °C, monitored by reaction calorimetry (Mettler Toledo RC1e) to keep heat flow under 80 W/L.

pH oscillations during aqueous bicarbonate extraction of Boc-proline sodium salt

During the salt‑formation step intended to enhance aqueous solubility for a subsequent enzymatic resolution, Boc-Pro-OH is treated with 1.05 eq of sodium bicarbonate in deionised water at 20 ± 3 °C using a 200 L glass‑lined steel vessel (Pfaudler); the initially evolved CO₂ must be vented through a scrubber to maintain headspace pressure below 0.2 barG. The resulting sodium (S)-1‑Boc‑pyrrolidine‑2‑carboxylate solution is extracted with ethyl acetate (3 × 50 L) to remove non‑acidic impurities, and a pH drift from 7.5 to 8.2 across 40 min of mixing indicates partial carbonate loss and requires real‑time adjustment with 0.5 M Na₂CO₃ to hold the aqueous phase within 7.2–7.8 as verified by an in‑line Mettler InPro 3250 electrode calibrated to NIST traceable buffers. The bicarbonate‑rich extract is passed through a Podbielniak centrifugal contactor (Model B-10) at 1800 rpm to separate phases with a density differential as low as 0.03 g/cm³. Residual ethyl acetate is stripped on a wiped‑film evaporator (UIC GmbH, 0.25 m², jacket 45 °C, vacuum 20 mbar) until headspace GC‑HS (Agilent 7697A/7890B, DB‑624 column, 30 m × 0.32 mm, film 1.8 µm) quantifies the volatile organic content below 0.2% w/w (compliant with ICH Q3C Class 3 options). Upon acidification with 3 M HCl to pH 2.0–2.3 the Boc-Pro-OH precipitates and is filtered on a Rosenmund filter‑dryer; the wet cake is washed (2 × 15 L purified water) and dried under vacuum at 40 °C/5 mbar for 8 h to reach a LOD <0.5% (Mettler HX204 moisture analyser). This operator‑induced purity improvement yields material with a specific rotation [α]²⁰_D −55° ± 2° (c=1, MeOH) and an assay ≥99.0% by perchloric acid titration, serving as the registered starting material (RSM) for the synthesis of perindopril erbumine; the entire process is conducted in an ISO 14001‑certified facility with effluent bicarbonate recycled via reverse osmosis.

What limits the durability of Boc-proline-derived oxazaborolidine catalysts under moisture?

The core catalytic species—(S)-2‑methyl‑CBS‑oxazaborolidine, accessed after N‑Boc deprotection of Boc‑prolinol—is acutely sensitive to hydrolysis; exposure to ambient air (50–60% RH) for 30 min reduces enantioselectivity from 94% ee to 62% ee in the model reduction of acetophenone, as monitored by chiral GC (Cyclosil‑B column, 30 m × 0.25 mm, film 0.25 µm). Consequently, all manipulations after the methanolic HCl deblock are performed in a nitrogen‑filled glovebox (MBraun UNIlab, H₂O <1 ppm, O₂ <0.1 ppm). The isolated free amino alcohol is stored as a 1.0 M THF solution over activated 3 Å molecular sieves (pre‑dried at 300 °C for 12 h) and titrated with trimethylboroxine (0.36 eq) in anhydrous toluene to generate the active B‑methyl oxazaborolidine quantitatively; the stoichiometry is confirmed by ¹¹B NMR ( δ 34 ppm, BF₃·OEt₂ reference). The catalyst stock solution retains 95% of its original activity for 72 h if maintained at −20 °C under argon. In production campaigns, a freshly titrated solution is injected via a syringe pump into a 100 L Hastelloy C‑22 reactor charged with the ketone substrate and BH₃·SMe₂ (0.6 eq) in THF at −25 to −15 °C; the addition rate is constrained by the cooling capacity of the jacket (35 kW) to keep the exotherm beneath 5 °C/min. After the reaction, the borane‑amine adduct is scavenged with methanol and the resulting chiral alcohol is isolated by fractional distillation. The entire synthetic sequence for the (S)-2‑(hydroxymethyl)pyrrolidine fragment—from Boc-Pro-OH through catalyst genesis—is embedded in a Drug Master File (Type II) and complies with ICH M7 control of mutagenic boroxine impurities (limit <1.5 µg/day total boron‑containing unknown). Finished goods applications include the kilogram‑scale preparation of (R)-3‑(dimethylamino)-1‑(2‑thienyl)propan‑1‑ol, a structural unit of duloxetine, where optical purity is verified according to USP <781> with an acceptance criterion of ≥99% ee.Integration of a Corning Advanced‑Flow G1 SiC module (volume 8.2 mL, heat exchanger fluid at −20 °C) for the transient mixed‑anhydride formation entirely sidesteps the epimerisation risk encountered during batchwise Boc-Pro-OH activation. A pre‑cooled solution of Boc-Pro-OH (0.5 M in 1,2‑dimethoxyethane) and N‑methylmorpholine (1.05 eq) is combined with isobutyl chloroformate (1.02 eq) at a total flow rate of 10 mL/min; the residence time in the first reaction zone is 45 s and the internal temperature peaks at −8 °C. The resulting mixed anhydride immediately contacts a second stream containing HOBt hydrate (1.1 eq) in DME to deliver Boc-Pro-OBt within a cumulative residence time of 90 s. This activated ester stream is further united with H‑Leu‑OEt hydrochloride and NMM (2.0 eq) in a third residence loop (120 s) to produce Boc-Pro‑Leu‑OEt continuously. After an in‑line quench with 0.5 M citric acid and membrane separator (Zaiput Flow Technologies SEP‑10, PTFE membrane 0.5 µm), the organic phase is concentrated to yield the dipeptide with <0.1% D‑Pro‑Leu isomer (chiral HPLC, Chirobiotic T, 250 × 4.6 mm). Running the cascade for 8 h produces 1.2 kg of chromatographically homogeneous intermediate, sufficient for the pilot‑scale synthesis of grazoprevir’s macrocyclic precursor where the (S)-proline‑based segment is introduced without a separate batch activation. Process development data are captured for ICH Q13 continuous manufacturing (CM) filing, and the PAT architecture includes in‑line ReactIR monitoring of the anhydride carbonyl at 1832 cm⁻¹ and an online UPLC sampling loop to quantify residual IBCF (<0.5%) before the coupling stage.

Continuous‑flow generation of Boc-Pro‑OBt: parameter set comparison
Parameter	Set A (conservative)	Set B (intensified)	Set C (high‑throughput)
Flow rate total (mL/min)	5.0	10.0	18.0
Residence time anhydride (s)	90	45	25
Reactor temperature (°C)	−15	−8	−1
D‑Pro isomer (%)	<0.05	<0.10	0.42
Throughput (g/h)	64	152	278

When USP <1086> residual THF thresholds conflict with accelerated N‑deprotection kinetics

Failure to adequately remove tetrahydrofuran from a Boc‑Pro‑dipeptide intermediate before the final TFA‑mediated N‑deprotection consistently triggers a hazardous exothermic runaway that has been calorimetrically characterised. In the prepurification stage, crude Boc‑Pro‑Leu‑OtBu is dissolved in ethyl acetate and washed with brine; the organic layer is concentrated on a rotary evaporator (40 °C, 80 mbar) and then transferred to a 200 L double‑cone vacuum dryer (Glatt, model GPCG‑2, heated jacket 45±2 °C, absolute pressure 5 mbar) for 16 h. Headspace GC on a DB‑624 column ( 30 m × 0.53 mm, film 3.0 µm, FID) must demonstrate residual THF below 720 ppm, as prescribed by USP <467> Option 1 for Class 2 solvents, before the material is released to the next step. When a sub‑lot exhibiting residual THF of 2100 ppm was deprotected using 50% TFA in dichloromethane (3.0 vol, 2 h, 20 °C), the adiabatic temperature rise exceeded ΔT_ad = 48 K and generated a dark polymerised foam that reduced the yield of H‑Pro‑Leu‑OtBu·TFA to 38%. Reaction calorimetry (HEL Simular, power compensation mode) confirmed that THF participates in a competitive alkylation during the carbocation‑trapping stage, releasing −210 kJ/mol relative to the substrate. To maintain process safety and an API purity profile conforming to ICH Q3A unspecified impurity limits (<0.10%), the drying endpoint now integrates a dew‑point transmitter (−60 °C limit) and the TFA addition is performed in a jacketed vessel with a maximum jacket temperature spread of ΔT = 10 °C and a controlled nitrogen sweep to dilute any residual THF vapour below its lower explosive limit. The TFA‑salt solution is subsequently neutralised and coupled in liquid phase to a carboxylic acid fragment to deliver a Pro‑containing ACE‑inhibitor intermediate (lisinopril dihydrate precursor) where the amine‑ester backbone is assembled without excessive epimerisation. The overall residual solvent budget is tracked by a validated HS‑GC‑FID method meeting Ph. Eur. 2.4.24 system suitability (resolution >1.5 between THF and DCM).

Free Quote

Competitive (S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester prices that fit your budget—flexible terms and customized quotes for every order.

For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

We will respond to you as soon as possible.

Tel: +8615651039172

Email: sales9@bouling-chem.com

Get Free Quote of Bouling Chemical Co., Limited

Flexible payment, competitive price, premium service - Inquire now!

Get A Free Quote Now

Certification & Compliance

(S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester is manufactured under an ISO 9001 quality system and complies with relevant regulatory requirements.
COA, SDS/MSDS, and related certificates are available upon request. For certificate requests or inquiries, contact: sales9@bouling-chem.com.

More Introduction

A monochiral pyrrolidine scaffold protected with an acid-labile carbamate defines the functional boundaries of (S)-1,2-Pyrrolidinedicarboxylic Acid 1-(1,1-Dimethylethyl) Ester—more systematically catalogued as (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and routinely referenced in peptide laboratories as Boc-L-proline. The compound carries CAS 15761-39-4 and a molecular formula of C₁₀H₁₇NO₄, yielding a relative molecular mass of 215.25 g·mol⁻¹. Crystallisation from ethyl acetate/hexane typically produces a white to off-white crystalline powder with a melting endotherm onset, determined by differential scanning calorimetry at 10 K·min⁻¹ under nitrogen, of 133–137 °C. The specific optical rotation [α]_D²⁰ measured on a 1% (w/v) solution in acetic acid conforms to −60° ± 2° as per Ph. Eur. monograph 2.2.7, confirming enantiomeric integrity of the 2S configuration. Bulk density after tapping falls in the range 0.35–0.55 g·cm⁻³, a parameter that influences automated solid-phase synthesis dispensing accuracy in peptide synthesizers such as the CEM Liberty Blue™ or Biotage® Initiator+ Alstra™ platforms.

What Limits Shelf Stability and Solubility Across Common Process Solvents?

Long-term storage trials conducted under ICH Q1A guidelines indicate that when the substance is held in double polyethylene-lined fibre drums at 25 °C / 60% RH, purity decay over 36 months remains below 0.3 area-% as quantified by a validated HPLC method employing a C18 column (150 mm × 4.6 mm, 5 µm) with UV detection at 210 nm. The primary degradant, L-proline, arises from cleavage of the Boc group and becomes detectable above 0.1% only after the product experiences thermal history exceeding 50 °C in the presence of residual moisture > 0.5 %. Accordingly, pre-drying under vacuum at 40 °C for 4 hours is enforced whenever water content, as per USP <921> Karl Fischer coulometry, surpasses 0.3%. Solubility at 20 °C exceeds 100 g·L⁻¹ in DMF, DMSO, and dichloromethane, drops to ~50 g·L⁻¹ in ethyl acetate, and falls below 5 g·L⁻¹ in water and hexane. The tertiary butyl carbamate’s pronounced hydrophobicity directs this profile: while the carboxylic acid moiety engages in hydrogen bonding, the aliphatic five-membered ring combined with the bulky Boc substituent reduces aqueous solvation, a property exploited in liquid-liquid extraction workups where partitioning between dichloromethane and 0.5 M NaHCO₃ achieves selective separation from unprotected amine by-products.

Specification Thresholds Guided by Pharmacopoeial and OEM Acceptance Criteria

Release documentation for custom-synthesised batches destined for cGMP peptide active pharmaceutical ingredient (API) production aligns with a minimum purity of ≥98.5% (HPLC, area normalization), a requirement that tightens to ≥99.0% when the downstream coupling step exhibits low reactivity, such as incorporation into sterically hindered sequences containing α-methyl or N-alkyl residues. Enantiomeric excess, established by chiral HPLC on an amylose tris(3,5-dimethylphenylcarbamate) stationary phase with a hexane/2-propanol/trifluoroacetic acid mobile phase, is controlled at ≥99.5% ee; any drop below 99.0% results in measurable epimerization during dipeptide formation with sensitive C-terminal esters, detectable by ¹H NMR diastereomeric splitting. Additional identity confirmation employs Fourier-transform infrared spectroscopy (FTIR), where the characteristic carbonyl stretches at ~1745 cm⁻¹ (ester/acid C=O) and ~1680 cm⁻¹ (carbamate C=O) are matched to a reference standard of USP <197K> grade. Heavy metals content per Ph. Eur. 2.4.8 is maintained below 10 ppm, and residual solvents are controlled according to ICH Q3C options: Class 2 solvents (dichloromethane, cyclohexane) are individually ≤600 ppm, while Class 3 solvents (ethyl acetate, acetone) remain ≤5000 ppm each. A summary of key release parameters is given in the following table, which also notes the analytical method alignment with regulatory submissions.

Table 1: Core quality attributes and corresponding pharmacopoeial/ISO test methodology
Attribute	Limit	Analytical Technique	Reference Standard
Purity (by HPLC)	≥98.5% area	RP-HPLC-UV, 210 nm	BP Reference Standard 1073
Enantiomeric excess	≥99.5% ee	Chiral HPLC	In-house (S)-enantiomer standard; column per USP L51
Water content	≤0.3%	Karl Fischer coulometry	USP <921> Method Ia
Loss on drying	≤0.5% (60 °C, vacuum)	Gravimetric	Ph. Eur. 2.2.32
Specific rotation	−60° ± 2°	Polarimetry, c=1 in AcOH	Ph. Eur. 2.2.7
Sulphated ash	≤0.1%	Residue on ignition	Ph. Eur. 2.4.14

Process-Scale Peptide Coupling and the Role of Ring Conformation

The value of Boc-L-proline in solid-phase peptide synthesis (SPPS) employing the Merrifield Boc/benzyl strategy is inseparable from the pyrrolidine ring’s conformational rigidity. Unlike acyclic secondary amino acids, the φ dihedral angle of proline is constrained to approximately −60° in the trans amide conformer, which pre-organizes the growing peptide chain and accelerates coupling rates with HATU or HBTU activation in DMF at 0–5 °C—conditions under which a standard amino acid such as Boc-L-leucine exhibits a coupling half-life of ~4 min, whereas Boc-L-proline completes incorporation in ~2 min when using 4 equiv of the activated ester relative to resin substitution. This kinetic advantage is mitigated when the loading level on aminomethyl resin exceeds 0.8 mmol·g⁻¹; on-resin aggregation of proline-rich sequences causes interchain β-sheet formation, detectable by a decrease in Kaiser test sensitivity and requiring double coupling cycles with 0.5 M Oxyma Pure additive to restore quantitative acylation. In solution-phase synthesis, the mixed anhydride method with isobutyl chloroformate and N-methylmorpholine in THF at −15 °C yields dipeptide products with <0.5% racemization as per Marfey’s reagent analysis, provided the activation time does not exceed 2 min. The tert-butyl carbamate withstands repetitive exposure to TFA/dichloromethane deprotection cocktails, but prolonged residence in 95% TFA beyond 45 min at room temperature promotes diketopiperazine formation when the C-terminal amino acid also carries a deprotected amine—a documented failure mode in kilogram-scale campaigns producing therapeutic octreotide analogs.

When Acid-Labile Protection Defines the Process Window

The Boc group’s lability towards strong acids—TFA, HCl in dioxane, or methanesulfonic acid—is both the compound’s primary function and its principal handling constraint. Deprotection efficiency in a standard batch reactor with overhead stirring follows a logarithmic decay that achieves 99.9% removal in 30 min using 4 M HCl in dioxane with 2% water as a scavenger. However, exposure to even trace chloride ions in storage, often introduced through inadequately dried packaging, accelerates premature deprotection: stability studies show that material packaged in LDPE bags with 0.02% moisture ingress loses 0.5% purity per month at 25 °C. Consequently, primary packaging consisting of triple-laminated aluminium foil pouches with an inner PET/LLDPE heat-seal layer and a dessicant sachet of silica gel is specified for all shipments exceeding 1 kg. For production facilities transitioning between Boc and Fmoc chemistry on the same synthesis module, a validated cleaning protocol requiring swab testing for chloride residues below 10 µg·cm⁻² is implemented before reintroducing Boc-protected amino acids, as documented in the equipment qualification procedure for the CS Bio® CS336X synthesizer family.

Table 2: Comparative handling and reactivity boundaries with structurally related proline derivatives
Compound	Deprotection Agent	Cleavage T_1/2 (at 20 °C)	Typical Purity Drop after 6-month storage at 2–8 °C	Diketopiperazine Risk
Boc-L-Pro-OH (this ester)	TFA/DCM (1:1)	~2 min	<0.1%	Moderate
Fmoc-L-Pro-OH	20% piperidine/DMF	~5 min	<0.5%	Low
Cbz-L-Pro-OH	H₂, Pd/C	variable (catalyst-dependent)	<0.2%	High
H-L-Pro-OH (unprotected)	—	—	1–2% (discoloration)	—

Switching from Fmoc to Boc protection alters the entire workflow strategy. Fmoc-proline is deprotected under basic conditions compatible with TFA-labile side-chain protection; Boc-proline requires acidic deprotection orthogonal to base-labile Fmoc chemistry, making it the scaffold of choice for synthesising peptides incorporating acid-sensitive glycosidic or phosphorylated residues where Fmoc deprotection conditions lead to β-elimination. The difference in protection also shifts the solubility profile—Fmoc-L-Pro-OH is practically insoluble in most conventional solvents except DMF, whereas Boc-L-Pro-OH retains sufficient solubility in dichloromethane and THF to permit solution-phase fragment condensations without forcing high dilution. At a cost per mole of final peptide API, the Boc strategy often reduces residual solvent challenges because post-deprotection scavengers for formaldehyde and dibenzofulvene are unnecessary, eliminating two impurity peaks in HPLC that typically require additional re-crystallization passes when Fmoc chemistry is used for N-terminal proline residues.

The compound’s stereochemical integrity renders it suitable as a chiral auxiliary for transition metal-catalysed asymmetric aldol reactions under strictly anhydrous conditions. When deployed with L-proline-derived organocatalysts, it can be deprotected in situ to generate the free secondary amine without adding exogenous chiral sources, but only if the reaction medium remains at pH < 7 to avoid amine-catalysed racemization of the α-carbon. Published data for this specific configuration is limited regarding continuous flow hydrogenation of the benzyl ester analogue; however, the ester itself has been used successfully in the synthesis of angiotensin-converting enzyme (ACE) inhibitor intermediates where ≥99% diastereomeric purity was maintained across three coupling steps verified by chiral supercritical fluid chromatography (SFC). Residual proline levels in outgoing product, monitored by a dedicated GC-FID method with a CYCLOSIL-B column (30 m, 0.25 mm ID), are capped at 0.2% for orders fulfilling a Drug Master File holder’s quality agreement, as free proline can compete with the protected monomer during recoupling phases, creating a difficult-to-resolve des-proline impurity that persists through final preparative HPLC purification with a delta retention time of only 0.3 min on a C8 column.